Skip to main content

Advertisement

Table 2 Association of main baseline characteristics of RA patients with DAS28 remission at 1 year (univariate analysis)

From: Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort

  DAS28 remission at 1 year P value OR (95 % CI)
yes no   
Age (years) 46.5 ± 12.6 49.6 ± 11.3 0.01 0.98 (0.96–0.99)
Females (%) 75 86 0.01 0.49 (0.29–0.82)
Body mass index (kg/m2) 24.6 ± 4.4 25.5 ± 4.6 0.06 0.96 (0.91–1.00)
Rheumatoid factor positivity (%) 51.3 51.1 0.97 1.01 (0.67–1.51)
Anti-citrullinated protein antibody positivity (%) 46.8 43.7 0.55 1.14 (0.75–1.71)
mSharp score 3.53 ± 4.02 3.75 ± 4.49 0.61 0.99 (0.94–1.04)
DAS28(ESR)-4v 4.98 ± 1.18 5.49 ± 1.16 0.00 0.69 (0.57–0.823)
logCRP (log-mg.l−1) 1.01 ± 0.47 1.03 ± 0.49 0.73 0.93 (0.59–1.44)
ESR 25 ± 22 29 ± 24 0.07 0.99 (0.98–1.00)
Steroids (%) 87.8 85.6 0.53 1.21 (0.66–2.22)
Use of cDMARD (%) 78.7 79.6 0.83 1.95 (0.57–1.57)
logOPG/TRAIL ratio Q <25 (%) 31.4 20.6   1.76 (1.11–2.81)a*
logOPG/TRAIL ratio Q25–75 (%) 41.7 51.7 0.015  
logOPG/TRAIL ratio Q >75 (%) 26.9 23.7   1.19 (0.74–1.89)b
  1. Data are mean ± SD (median) or percentage. Student t test for continuous variables and chi-square test for categorical variables
  2. RA rheumatoid arthritis, DAS28 Disease Activity Score in 28 joints, OR odds ratio, 95 % CI, 95 % confidence interval, cDMARD conventional disease-modifying anti-rheumatic drug (used at least at two visits), CRP C-reactive protein, DAS28(ESR)-4v Disease Activity Score in 28 joints, calculated with erythrocyte sedimentation rate (ESR) and four values, mSharp score van der Heijde-modified Sharp score, OPG osteoprotegerin, TRAIL tumor necrosis factor-related apoptosis-inducing ligand, Q <25 quartile <25th percentile, corresponding to 0.932, Q >75 quartile >75th percentile, corresponding to 1.039
  3. *p <0.05 p value for comparison of aQ <25th versus ≥25th percentile and bQ >75th versus ≤75th percentile